FDA approves genetic test for lung cancer drug

The Food and Drug Administration says it approved a genetic test from Roche to help doctors identify patients who can benefit from a lung cancer drug made by Genentech.

The diagnostic test is the first approved to detect found in roughly 10 percent of patients with the most prevalent form of lung cancer, known as non-small cell lung cancer.

Patients who test positive for the mutation are more likely to respond to Genentech's drug Tarceva as a first-choice treatment, and the FDA expanded the drug's approval for that use in an announcement Tuesday. The drug was previously approved only as a second-line option after patients had failed to respond to chemotherapy.

Lung cancer is the deadliest form of cancer among both men and women in the U.S.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

New treatment holds promise for resistant lung cancer

Apr 09, 2013

A new chemotherapy regimen appears to produce minimal side effects in patients with lung cancer that has not responded to previous therapy, paving the way for additional research to determine if the new regimen also helps ...

Recommended for you

Merck completes sale of consumer unit to Bayer

5 hours ago

Drugmaker Merck said Wednesday that it completed the sale of its consumer care business, which makes products including Claritin allergy medication and Coppertone sun-care line, to German health care company Bayer for $14.2 ...

Viagra ads target women for first time

Sep 30, 2014

The maker of the world's top-selling erectile dysfunction drug on Tuesday will begin airing the first Viagra TV commercial in America that targets the less-obvious sufferers of the sexual condition: women.

User comments